Aclaris Therapeutics Inc (NASDAQ:ACRS) has earned an average rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $47.25.
Several research analysts have weighed in on the company. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 17th. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Friday, August 3rd. BidaskClub downgraded Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 25th. Finally, JMP Securities lowered their target price on Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating on the stock in a research note on Tuesday.
Shares of ACRS stock opened at $12.17 on Tuesday. Aclaris Therapeutics has a twelve month low of $11.00 and a twelve month high of $27.20.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The company had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.76 million. On average, research analysts anticipate that Aclaris Therapeutics will post -5.38 EPS for the current year.
In other Aclaris Therapeutics news, Director Stephen A. Tullman purchased 6,600 shares of Aclaris Therapeutics stock in a transaction dated Thursday, August 23rd. The stock was acquired at an average cost of $15.00 per share, with a total value of $99,000.00. Following the acquisition, the director now directly owns 170,357 shares of the company’s stock, valued at $2,555,355. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Stephen A. Tullman purchased 6,250 shares of Aclaris Therapeutics stock in a transaction dated Wednesday, August 15th. The stock was acquired at an average cost of $15.97 per share, with a total value of $99,812.50. Following the completion of the acquisition, the director now directly owns 163,757 shares in the company, valued at $2,615,199.29. The disclosure for this purchase can be found here. Insiders bought a total of 19,950 shares of company stock valued at $298,213 over the last three months. Insiders own 17.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of Aclaris Therapeutics by 561.0% in the 1st quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 5,531 shares during the period. Bank of Montreal Can acquired a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at approximately $159,000. Granite Investment Partners LLC acquired a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at approximately $164,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Aclaris Therapeutics by 518.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 7,009 shares during the period. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at approximately $200,000. 99.75% of the stock is owned by institutional investors and hedge funds.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Featured Article: Stock Split
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.